医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate Founder and CEO Receives PharmaVOICE 100 Award

2014年08月04日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO

Life science market intelligence company, Evaluate, Ltd., announced today that Founder and CEO, Dr. Jonathan de Pass, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and influential people in the Life Sciences Industry.

The PharmaVOICE 100 represents leaders from across the global life sciences industry. A panel of PharmaVOICE editors chose the winners based on their ability to inspire, motivate and influence corporate leadership, research and development, technology, creativity and marketing and strategy.

Dr. de Pass founded Evaluate, Ltd. and the EvaluatePharma service from the ground up in 1996. Since then, Evaluate has come to be regarded as a trusted leader in life science market intelligence, known for its expertise, creativity and customer service by most of the world’s global pharmaceutical companies. A career highlight for Dr. de Pass was winning the Queens Award for Enterprise in 2009, one of the UK’s most prestigious business awards.

“For the 10 years I have worked with Jonathan, he has not only motivated me to always improve the way we manage and grow our services but has been an excellent person to work alongside, learn from and most importantly be inspired by,” said Debbie Paul, CEO, EvaluatePharma USA, Inc.

To read the 2014 PharmaVOICE 100 profiles, visit www.pharmavoice.com.

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren
+1
617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Rachel Lear
+1 781-775-3640
+1
858-457-2436
rlear@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Melanie Toyne Sewell
Gemma Howe
+44
(0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
  • Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
  • クリアがCOVID-19声明に関する政府の訴訟に対して修正答弁書を提出、クリア製品の追加防御層としての使用を支持するデータをさらに提供
  • Integral Group Australia Rebranding as Introba to Align with Global Brands
  • 针对政府就新冠病毒声明提起的诉讼,Xlear提交修正后的答复;通过更多数据继续支持Xlear作为额外防护层使用